Objective-To assess the effect of different doses of gabapentin (GBP) on cognitive function in treated epileptic patients. Methods-Twenty seven patients with refractory partial seizures commenced a double blind, dose ranging, placebo controlled, crossover study of adjuvant GBP. Each treatment phase lasted three months, during which the dose of GBP or matched placebo was increased stepwise at intervals of four weeks (1200 mg/day, 1800 mg/day, and 2400 mg/day in three daily doses). Psychomotor and memory testing was carried out at the end of each four week period, at which time the patient also completed subjective measures of cognition, fatigue, worry, temper, and dysphoria. A visual analogue scale was used to assess drowsiness and a questionnaire was employed to gauge the severity of side effects. Results-In the 21 patients completing the study, GBP produced a significant reduction in median monthly seizure frequency from 7 to 4-3 (P = 0-02), the decrease being most pronounced for secondarily generalised seizures (from 1 0 to 0 3, P = 0-01). Forty three per cent of patients reported a reduction in seizure frequency of at least 50% throughout all GBP doses. Mean (SD) plasma concentrations of GBP at 1200, 1800, and 2400mg/day were 4-7 (2.6), [6] [7] [8] (3.8), and 8'6 (3.3) mg/l respectively. The drug had no effect on composite psychomotor and memory scores; nor was there alteration in any self assessment subscore.
and 2400 mg/day in three daily doses). Psychomotor and memory testing was carried out at the end of each four week period, at which time the patient also completed subjective measures of cognition, fatigue, worry, temper, and dysphoria. A visual analogue scale was used to assess drowsiness and a questionnaire was employed to gauge the severity of side effects. Results-In the 21 patients completing the study, GBP produced a significant reduction in median monthly seizure frequency from 7 to 4-3 (P = 0-02), the decrease being most pronounced for secondarily generalised seizures (from 1 0 to 0 3, P = 0-01). Forty three per cent of patients reported a reduction in seizure frequency of at least 50% throughout all GBP doses. Mean (SD) plasma concentrations of GBP at 1200, 1800, and 2400mg/day were 4-7 (2.6), [6] [7] [8] All memory tests except for the paired associated learning, which was not undertaken at baseline, were performed at every visit. The forward digit span measured the maximum number of digits the patient could recall immediately after oral presentation. Patients were allowed two trials at each level. The backward digit span measured the maximum number of digits that the patient could recall immediately after oral presentation. Both digit span tests were discontinued when two were failed at the same level. The forward visual span measured the maximum number of squares correctly reproduced in sequence as shown by the examiner. The backward visual span assessed the maximum number of squares correctly reproduced in reverse order to that shown by the examiner. The visual span tests were terminated when two consecutive tests were failed. The paired associate learning test gave a score up to 18 depending on the number of attempts required by the patient to name three sets of correctly paired words. Composite memory scores were calculated in a similar manner to the composite psychomotor scores, providing a figure that gave equal weighting to each test. 9 The SEALS questionnaire involved 50 questions that assessed subjective feelings of cognitive slowing, dysphoria, irritability, fatigue, and worry.'4 The period under assessment was the seven days immediately before each clinic visit. The side effects score was constructed from patients' responses to a four point grading score for 10 adverse effects (dizziness, headache, nausea, double vision, tremor, unsteadiness, dry mouth, flushing, ankle swelling, and palpitations). Only the first six were regarded as being associated with antiepileptic drug use, the other four being controls. The combined score for the six recognised antiepileptic drug associated symptoms were obtained via simple addition as all symptoms were scored on the same four point scale. To undertake the drowsiness score, patients were asked to estimate, with the help of a visual analogue scale, their degree of alertness. The measured distance along a 10 cm line marked at either end "fully awake" and "nearly asleep" was recorded.
DRUG ASSAYS
Carbamazepine, sodium valproate, phenytoin, and phenobarbitone concentrations were measured by enzyme immunoassay (Emit, Syva, Palo Alto, USA). Vigabatrin was extracted from plasma into ethyl acetate, heated with dansyl chloride at high pH to form a fluorescent derivative, and measured by high performance liquid chromatography (HPLC) with phenyl GABA as internal standard. The interassay coefficient of variation (CV) over the range 1-100 mg/l was 5% and the lower limit of detection was 0-1 mg/l. ' 0-01). There was no significant difference in response between the patients taking one or two antiepileptic drugs before introduction of GBP.
NEUROPSYCHOLOGICAL TESTNG
No order effect was seen for any variable, nor was there a "learning effect" as the study progressed. Comparison of individual tests and composite psychomotor scores at each treatment level with the corresponding placebo phase failed to show any significant difference (table 2) . Mean composite psychomotor scores, however, showed a negative correlation (r = -0A47, P < 0 01) with seizure frequency (fig 1) , which reached significance during treatment with both placebo (r = -0 40, P = 0-02) and GBP (r = -0-45, P= 004).
The paired associate learning test was improved on 2400 mg GBP daily v placebo. No other memory test showed a difference between GBP and placebo at any dose. There was no difference in composite memory scores between GBP and placebo treatment (table 2) . No correlation was found between composite memory scores and seizure frequency during treatment with either placebo or GBP.
None of the five SEALS subscores was significantly affected by GBP even at the highest dose, although the increases in scores for cognition and fatigue ( 20 Were the highest dose levels to be observed for longer, perhaps this phenomenon would have been found here. Although multiple comparisons may provide isolated significant results, the fact that the composite scores measured closely allied symptoms suggests that these findings may be clinically as well as statistically significant. The significant correlation between seizure frequency and composite psychomotor, tiredness, and side effect scores is interesting. Whether this reflects impairment of an innately more damaged brain or is secondary to the seizures themselves is difficult to assess. That the correlation between seizure frequency and these variables was much stronger than that with GBP dosage and concentration does imply, however, that optimal improvement in quality of life in epileptic patients can be gained by reducing seizure frequency with drugs that do not impair cognition.
